dc.contributor.author | Pathmanathan, AU | |
dc.contributor.author | Alexander, EJ | |
dc.contributor.author | Huddart, RA | |
dc.contributor.author | Tree, AC | |
dc.date.accessioned | 2017-03-01T12:54:00Z | |
dc.date.issued | 2016-11-01 | |
dc.identifier.citation | Future oncology (London, England), 2016, 12 (21), pp. 2495 - 2511 | |
dc.identifier.issn | 1479-6694 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/450 | |
dc.identifier.eissn | 1744-8301 | |
dc.identifier.doi | 10.2217/fon-2016-0129 | |
dc.description.abstract | Dose escalation to the prostate improves tumor control but at the expense of increased rectal toxicity. Modern imaging can be used to detect the most common site of recurrence, the intraprostatic lesion (IPL), which has led to the concept of focusing dose escalation to the IPL in order to improve the therapeutic ratio. Imaging must be able to detect lesions with adequate sensitivity and specificity to accurately delineate the IPL. This information must be carefully integrated into the radiotherapy planning process to ensure the dose is targeted to the IPL. This review will consider the role and challenges of multiparametric MRI and PET computed tomography in delineating a tumor boost to be delivered by external beam radiotherapy. | |
dc.format | Print-Electronic | |
dc.format.extent | 2495 - 2511 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | FUTURE MEDICINE LTD | |
dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
dc.subject | Humans | |
dc.subject | Prostatic Neoplasms | |
dc.subject | Magnetic Resonance Imaging | |
dc.subject | Neoplasm Staging | |
dc.subject | Radiotherapy Dosage | |
dc.subject | Radiotherapy Planning, Computer-Assisted | |
dc.subject | Reproducibility of Results | |
dc.subject | Male | |
dc.subject | Multimodal Imaging | |
dc.subject | Positron Emission Tomography Computed Tomography | |
dc.title | The delineation of intraprostatic boost regions for radiotherapy using multimodality imaging. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2016-05-01 | |
rioxxterms.versionofrecord | 10.2217/fon-2016-0129 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2016-11 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Future oncology (London, England) | |
pubs.issue | 21 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart) | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart) | |
pubs.publication-status | Published | |
pubs.volume | 12 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Clinical Academic Radiotherapy (Huddart) | |
dc.contributor.icrauthor | Huddart, Robert | |